The present invention relates to inactivated stem cells, which can be stored for several days in a refrigerator (above 0° C.), preferably in the range 0.1-10° C.) and still maintain their cellular and phenotypic integrity as well as therapeutic potential. In particular, the present invention relates to medical uses of such refrigerator-stored inactivated stem cell solution.
The disclosure regards a collimation system for a radiotherapy system, the collimation system comprising: a first multi-slit collimator having multiple first parallel slits, the first multi-slit collimator being adapted to be placed between a radiation source and an object, a second multi-slit collimator having multiple second parallel slits, the second multi-slit collimator being adapted to be placed between the first multi-slit collimator and the object, and a controller for holding and adjusting a relative slit orientation between the multiple first parallel slits of the first multi-slit collimator and the multiple second parallel slits of the second multi-slit collimator by rotating at least one of the first multi- slit collimator and the second multi-slit collimator around a beam axis between the radiation source and the object. The disclosure further relates to a radiotherapy system and a method of controlling multi-slit collimators in a radiotherapy system.
The disclosure regards a variable slit collimator for a radiotherapy system, such as a spatially fractionated radiotherapy system, comprising a plurality of collimator leaf pairs, each collimator leaf pair comprising two tapered collimator leaves abutting each other to form a leaf of the variable slit collimator, and a leaf adjustment mechanism for moving the two tapered collimator leaves towards and away from each other in a longitudinal direction of the two tapered collimator leaves to adjust the leaf width of the variable slit collimator. The disclosure further relates to a radiotherapy system and to a method of controlling a slit collimator in a radiotherapy system, such as a spatially fractionated radiotherapy system.
The present invention relates to proteinaceous prodrug constructs, e.g., proteinaceous fusion constructs that comprise a complement 3- and pregnancy zone protein-like, alpha-2 -macroglobulin domain-containing (CPAMD) protein (e.g., A2M) and one or more drugs and function as protease- activatable prodrugs. The invention further relates to a release mechanism from the CPAMD protein and the development of multispecific, such as bi-specific, drugs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
5.
SYMRK PHOSPHORYLATION FOR ROOT NODULE ORGANOGENESIS
The present disclosure relates to modified plant SYMRK polypeptides that constitutively induces symbiotic organogenesis or induces symbiotic organogenesis in the absence of rhizobial bacteria and/or arbuscular mycorrhizal fungi recognized by the plant at a higher level than the unmodified plant SYMRK polypeptide under the same conditions and use thereof in plants.
The present disclosure relates to modified plant SYMRK polypeptides that constitutively induces symbiotic organogenesis or induces symbiotic organogenesis in the absence of rhizobial bacteria and/or arbuscular mycorrhizal fungi recognized by the plant at a higher level than the unmodified plant SYMRK polypeptide under the same conditions and use thereof in plants.
The present invention relates to proteinaceous prodrug constructs, e.g., proteinaceous fusion constructs that comprise a complement 3- and pregnancy zone protein-like, alpha-2-macroglobulin domain-containing (CPAMD) protein (e.g., A2M) and one or more drugs and function as protease-activatable prodrugs.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
The present application relates to a fusion protein comprising: an antibody or antigen-binding fragment thereof that binds to C3b; and a polypeptide that binds to C3b, wherein the polypeptide comprises: (i) the amino acid sequences according to SEQ ID NO: 11 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 11; and (ii) the amino acid sequences according to SEQ ID NO: 12 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12, wherein the antibody or antigen-binding fragment thereof of the fusion protein does not compete for binding to C3b with the polypeptide of the fusion protein. The application also provides polypeptides, nucleic acids, vectors and methods of preparing these as well as methods of treatment and pharmaceutical compositions.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The present invention relates to a lentivirus-derived particle comprising one or more Cas9-like proteins and at least one optimized sgRNA, wherein the optimized sgRNA comprises a targeting region and a non-targeting region, wherein said non-targeting region comprises a nucleotide sequence corresponding to SEQ ID NO: 1 or sequences having at least 90% sequence identity to SEQ ID NO: 1, said nucleotide sequence further comprising at least the following modifications: an extended repeat-anti-repeat region comprising a first extension of 2-8 base pairs in the repeat-anti-repeat region corresponding to nucleotides 1-12 and 17-30 of SEQ ID NO: 1; and optionally, an extended stem-loop 2 region comprising a second extension of 2-8 base pairs in the stem-loop 2 corresponding to the nucleotides 48-61 of SEQ ID NO: 1; and/or optionally, an A-U flip of the nucleotides corresponding to nucleotides 5 and 36 of SEQ ID NO: 1.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The present disclosure relates to modified plant LysM receptor polypeptides with modified intracellular domains, specifically, modified αA motifs and/or modified αA′ motifs in the juxtamembrane domain. The present disclosure further relates to genetically modified plants including the modified plant LysM receptor polypeptides, and methods of producing the same.
The present disclosure relates to genetically modified plant LysM receptors and methods of producing the same. In particular, the present disclosure relates to modified plant LysM receptors including a modified juxtamembrane (JM) zone 4, and optionally further including a modified JM zone 2, a modified JM zone 3, a modified extracellular domain, and/or a modified kinase C-terminus region or a modified kinase N-terminus region. The modified LysM receptors of the present disclosure are either able to able to initiate NFR1-mediated root nodule symbiosis signaling or able to initiate ROS signaling. In addition, the present disclosure relates to genetically modified plants or parts thereof including the genetically modified plant LysM receptors and methods of producing the same. The present disclosure further relates to expression vectors, isolated DNA molecules, or recombinant nucleic acids encoding the genetically modified plant LysM receptors.
The present disclosure relates to a process of expanding hematopoietic stem cells (HSCs), a process of providing a pre-conditioned media, and the pre-conditioned media obtainable by thereby, uses of HI-MSCs and the pre-conditioned media and the expanded HSC population of cells, for use as a medicament.
A device and a method for image reconstruction for medical imaging is provided. The method comprises obtaining a PET image and dividing the PET image into localized subset images, each subset image being analyzed by a trained machine learning system obtaining an output for each subset image processed by the machine learning system and determine a representation output based on the outputs.
The invention regards a system and a method for a continuous methanation process comprising a plurality of parallel methanation reactors wherein each one of the plurality of parallel methanation reactors comprises a first sensor configured to provide a first output based on a measured parameter of a first fluid flow, and/or wherein the system comprises a clock configured to provide time outputs at predetermined times, and wherein the system is configured to control a first fluid flow based on the first output and/or the time outputs. A method and a system for a discontinuous methanation process is also disclosed, wherein the system is configured to provide time outputs at predetermined times, or wherein the system is configured to determine a production level of a power source providing hydrogen for the system and to provide production level outputs based on the determined production level, and wherein the system is configured to control the first fluid flow based on the time outputs, or the production level outputs.
The present disclosure relates to genetically modified plant LysM receptors and methods of producing the same. In particular, the present disclosure relates to modified plant LysM receptors including a modified juxtamembrane (JM) zone 4, and optionally further including a modified JM zone 2, a modified JM zone 3, a modified extracellular domain, and/or a modified kinase C-terminus region or a modified kinase N-terminus region. The modified LysM receptors of the present disclosure are either able to initiate NFRI-mediated root nodule symbiosis signaling or able to initiate ROS signaling. In addition, the present disclosure relates to genetically modified plants or parts thereof including the genetically modified plant LysM receptors and methods of producing the same. The present disclosure further relates to expression vectors, isolated DNA molecules, or recombinant nucleic acids encoding the genetically modified plant LysM receptors.
The present disclosure relates to modified plant LysM receptor polypeptides with modified intracellular domains, specifically, modified αA motifs and/or modified αA' motifs in the juxtamembrane domain. The present disclosure further relates to genetically modified plants including the modified plant LysM receptor polypeptides, and methods of producing the same.
The present invention relates to Rufinamide (or active derivatives thereof) for use in the treatment of myotonia, such as myotonia congenita, paramyotonia congenita and myotonic dystrophy. The present invention also relates to a combinatorial composition comprising Rufinamide (or active derivatives thereof) and Lamotrigine (or active derivatives thereof) for use as a medicament.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
18.
SORLA MINI-RECEPTOR FOR TREATMENT OF ALZHEIMER'S DISEASE
The present invention concerns a polynucleotide construct encoding a mini-receptor of SORLA. The present invention further concerns a vector, a cell and/or a composition comprising said polynucleotide construct. The present invention further concerns a polypeptide representing a mini-receptor of SORLA. The present invention further concerns said vector, said cell and/or said composition comprising said poly nucleotide construct, for use in medicine. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in treatment, prevention and/or alleviation of Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of treating Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of increasing sAPPα in a cell. The present invention further concerns a method of decreasing Aβ38, Aβ40, and/or Aβ42 in a cell.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Disclosed are 13N-oxytocin molecules, methods of manufacture of 13N-oxytocin molecules and methods of use of 13N-oxytocin molecules in the determination of the distribution and kinetics of 13N-oxytocin molecules after craniofacial or other application methods.
The present disclosure relates to a visual alignment indicator for a nasal spray dispenser or an adapter for a nasal spray dispenser. The present disclosure further relates to nasal spray dispenser, and a nasal spray guide adapter for holding a nasal spray dispenser, comprising the visual alignment indicator, while dispensing a fluid product into a nostril of a user. One embodiment relates to a spray guide adapter for holding a nasal spray dispenser comprising a lower end and an elongated upper end for dispensing the nasal spray fluid into a nostril of a user, the spray guide adapter comprising a housing comprising a dispenser opening for inserting and holding the lower end of the nasal spray dispenser, and an alignment indicator configured for providing a user of the nasal spray dispenser with feedback on the orientation of the elongated upper end of the nasal spray dispenser in the nostril of the user.
The present invention relates to pluripotent stems cells restricted in their capability to differentiate into cell lineages different from Dopaminergic neuron progenitor cells and derivatives thereof by specific gene knockouts. In particular, the present invention relates to dopaminergic neuron progenitor cells or cell derivatives thereof obtained from these lineage-restricted pluripotent stem cells and uses thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to a process for obtaining aromatic diamine(s) from depolymerized polyurethane, said process comprising the steps of: a) providing a composition comprising the depolymerized polyurethane, wherein said depolymerized polyurethane comprises diamine(s) and polyol(s); b) adding an anti-solvent towards aromatic diamine(s) to the composition of step a) to provide a suspension comprising precipitated aromatic diamine(s); c) separating the precipitated aromatic diamine(s) from the remainder of the suspension of step b) to obtain said aromatic diamine(s); wherein the aromatic diamine(s) are selected from the group consisting of 2,4-diaminotoluene, 2,6-diaminotoluene, 2,4'-methylenedianiline and 4,4'-methylenedianiline, or any mixture thereof, wherein the polyol(s) have an average molecular weight of 800 g/mol to 15,000 g/mol, and wherein the anti-solvent towards aromatic diamine(s) has a polarity index of less than 3.0.
C07C 211/49 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
S0RL1 encodes the retromer-associated receptor SORL1 that functions in endosomal recycling. Rare variants in SORL1 have been associated with Alzheimer's disease (AD) and rare pathogenic variants are estimated to occur in up to 2.75% of early onset AD patients and in 1.5% of unrelated late onset AD patients. While truncation mutations are observed almost exclusively in AD patients, it is currently unknown which among the hundreds of rare missense variants identified in SORL1, are pathogenic. This question is addressed by relying on SORLl's distinct molecular architecture. First, a structure-guided sequence alignment was completed for all the protein domains. Next, proteins that contain domains homologous to those of SORL1 were identified, which include pathogenic variants for monogenic diseases. The analogous domain positions of these variants in the SORL1 protein sequence were identified and showed that variants in these positions similarly impair SORL1, and lead to AD. Together, the findings represent a comprehensive compendium on SORL1 protein variation and functional effects, which allowed for the prioritization of SORL1 genetic variants into high or moderate priority mutations. This compendium may be used by clinical geneticists for assessing variants they identify in patients, allowing further development of diagnostic procedures and patient counseling strategies. Ultimately, this compendium will inform investigations into the molecular mechanisms of endosomal recycling which will support the development of therapeutic treatment strategies for SORL1 variant-carrying patients.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
The present disclosure concerns antisense oligonucleotide (ASO) capable of binding to a target site on the pre-mRNA of SORL1. The present disclosure further concerns a composition comprising said ASO. The present disclosure further concerns an ASO for use in medicine. The present disclosure further concerns an ASO for use in the prevention, treatment and/or alleviation of Alzheimer's Disease (AD), or a disease or disorder associated with Alzheimer's Disease. The present disclosure further concerns a method for mediating exon skipping in SORL1 transcripts, a method of determining the efficiency of ASO mediated SORL1 exon skipping, a method for testing if a patient identified with a SORL1 mutation will benefit from treatment with an ASO mediating exon skipping, and a method of producing an ASO.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure relates to enhancing nitrogen fixation in legumes grown under high nitrate or nitrate stress conditions. In particular, the present disclosure relates to genetically modified plants with altered level or expression of FUN or FUN downstream targets, and methods of producing and growing the same. The present disclosure further relates to nodule senescence controlled by FUN and its downstream targets, as well as the regulation of FUN activity or expression by cellular zinc.
Herein is disclosed a method for determining the risk of a subject suffering from chronic kidney disease (CKD) having subclinical acidosis and/or acid retention, the method comprising a) measuring or sensing in a urine sample from a subject, the level of at least two biomarkers b) determining a score based on a relationship between the levels of the at least two biomarkers by comparing to a reference level; and c) classifying the score as a positive or negative score; wherein said subject is a) at risk of having subclinical acidosis and/or acid retention, if said score is negative; and b) not at risk of having subclinial acidosis and/or acid retention, if said score is positive.
The present disclosure relates to enhancing nitrogen fixation in legumes grown under high nitrate or nitrate stress conditions. In particular, the present disclosure relates to genetically modified plants with altered level or expression of FUN or FUN downstream targets, and methods of producing and growing the same. The present disclosure further relates to nodule senescence controlled by FUN and its downstream targets, as well as the regulation of FUN activity or expression by cellular zinc.
The present disclosure relates to synthetic approaches based on affinity peptides to drive assembly and activation of transmembrane receptor complexes. The present disclosure further relates to the core NFR1-NFR5 receptor complex initiating the cortical root nodule organogenesis program and the epidermal program, as well as the identification of barley receptor complexes that function in root nodule symbiosis.
The present disclosure relates to synthetic approaches based on affinity peptides to drive assembly and activation of transmembrane receptor complexes. The present disclosure further relates to the core NFR1-NFR5 receptor complex initiating the cortical root nodule organogenesis program and the epidermal program, as well as the identification of barley receptor complexes that function in root nodule symbiosis.
The present invention relates to a method for determining the amount of recycled polyester in a polyester containing material, the method comprising a) providing a polyester containing material; b) determining the δ13C value in the polyester containing material from step a); c) comparing said determined δ13C value to a corresponding reference table; and d) determining the amount of recycled polyester in the polyester containing material by comparing to the corresponding reference level.
The disclosure relates to a system and a method for optimizing the bacterial methanotrophy conditions inside covered manure tanks. One embodiment relates to a method for automatically controlling aerobic microbial methanotrophy in an upper crust of a ventilated livestock manure storage tank (A) having an airtight cover above the upper crust defining a headspace between the upper crust and the airtight cover, the method comprising the steps of continuously measuring a concentration of methane representing a concentration of methane in the headspace of the livestock manure tank, continuously monitoring a rate of change in the concentration of methane in the headspace of the livestock manure tank, and automatically adjusting a flow of ventilating air to the manure tank based on said monitored rate of change, said flow of ventilating air fluidly connecting the headspace of the livestock manure tank with outside atmospheric conditions, thereby optimizing conditions for aerobic microbial methanotrophy in the upper crust to reduce emission of methane from the manure storage tank.
The invention relates to means and methods for analysis of analytes using nanopore-based sensors, for example, to methods, nanopore systems and devices for the stochastic detection of (label-free) analytes in complex samples, for example the specific detection of a protein biomarker in a bodily sample. Provided is a method for detecting the presence of at least one analyte in a sample using a nanopore system comprising a cis chamber comprising a first conductive liquid medium in liquid communication with a trans chamber comprising a second conductive liquid medium through a modified nanopore, comprising: (a) adding a sample to be analyzed for the presence of an analyte to the cis chamber; (b) optionally applying an electrical potential across the modified nanopore; (c) measuring ionic current passing through the modified nanopore, wherein said modified nanopore is a biological nanopore that is functionalized with a 5 to 50 kDa, preferably 10 to 40 kDa, recognition element (e.g., proteinaceous recognition element) R capable of specifically binding to the analyte.
The present disclosure relates to a device, a kit and a method for image guided stereotaxic sampling and oriented sectioning of a biological specimen for correlating 3D medical imaging to spatial transcriptomics. One embodiment relates to a device for holding a biological specimen during medical imaging, said device comprising a non-magnetic supporting base and at least two rows of non-magnetic elements, wherein the device is configured for sustaining the biological specimen on the non-magnetic supporting base between the at least two rows of non-magnetic elements such that the biological specimen can be sliced along the non-magnetic elements into slices of a predetermined thickness and orientation after medical imaging. A method of correlating medical imaging and sampling of a biological specimen is also disclosed.
Mycobacterium tuberculosisMycobacterium tuberculosis (mt) by incubating a saliva sample from a subject with a single stranded DNA oligonucleotide comprising an STS binding element for mt DNA Topoisomerase I enzyme (mTOPI) and subsequently determining the level of circularized oligonucleotide. Furthermore, the present invention relates to oligonucleotides comprising an STS binding element and uses thereof.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
35.
CGMP COMPLIANT PRODUCTION AND EXPANSION OF PLASMACYTOID DENDRITIC CELLS FROM HEMATOPOIETIC STEM AND PROGENITOR CELLS
HSPC-derived Plasmacytoid dendritic cells (HSPC-pDCs) constitute a rare type of immune cell with multifaceted functions that bridge pivotal pants of the immune system. Biological studies of blood-derived HSPC-pDCs and their potential use as a cell-based immunotherapy have long been challenged by the scarce amounts of HSPC-pDCs that can be extracted from blood samples. This invention is related to a process for HSPC-pDC production applicable for clinical use, which involves in vitro differentiation of hematopoietic stem and progenitor cells (HSPCs). With this optimized GMP-compliant protocol, we generated an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord-blood derived HSPCs, and we also show that the protocol enables robust HSPC-pDC generation from HSPCs extracted from whole blood. The produced cells display a pDC phenotype (Lin−/CD11c−/CD123+/CD303+) and the ability to produce high levels of type I interferon upon TLR7 and TLR9 stimulation.
The present invention relates to albumin-oligodeoxynucleotides conjugates, such as compounds, and compositions comprising a protein conjugate, the conjugate comprising an albumin, one or more proteinaceous parts, and one or more CpG oligonucleotides (ODN). These compounds and compositions finds use as medicaments and/or vaccines, and in methods of treatment. Also disclosed are methods for producing the compound or the composition and kits comprising the necessary tools.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
The invention regards a system for controlling a biomethanation reactor comprising a biomethanation reactor comprising a first fluid inlet and a first fluid outlet, wherein the biomethanation reactor is configured for at least one first fluid flow between the first fluid inlet and the first fluid outlet defining a first direction of the at least one first fluid flow; a first gas concentration sensor configured to measure a first gas concentration at a first gas concentration sensor location within the biomethanation reactor, and/or at least a first temperature sensor and a second temperature sensor configured to measure a first temperature at a first temperature sensor location within the biomethanation reactor and a second temperature at a second temperature sensor location within the biomethanation reactor; respectively, and at least one controller configured to regulate the at least one first fluid flow into the biomethanation reactor based on the first gas concentration or on the first and second temperatures. A method for controlling a biomethanation reactor is also disclosed.
The present invention relates to a method for disassembly of epoxy-based polymers, the method comprising chemical manipulations to a cured epoxy resins involving a mixture of at least one organic solvent and a base. Specifically, the epoxy-based polymer is an amine-cured epoxy resin and the base is a nucleophilic base. The present invention allows for recycling of the constituents comprised in the cured epoxy resin in high yields, notably even in the absence of any metal catalyst.
C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
C08J 11/28 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic compounds containing nitrogen, sulfur or phosphorus
39.
METHODS FOR IMPROVING CORROSION AND WEAR RESISTANCE AND STRENGTH OF ESSENTIALLY NICKEL-FREE HIGH-MANGANESE AUSTENITIC STAINLESS STEEL COMPONENTS
Methods involving high temperature solution treatment that improve corrosion and wear resistance and strength of Ni-free high-Mn austenitic stainless steels are disclosed, together with Ni-free high- Mn austenitic stainless steels, articles and components so treated.
The present invention relates to isolated polypeptides derived from stanniocalcin-2 (STC2), and polypeptide fragments and variants thereof useful for inhibiting proteolytic activity of the pregnancy-associated plasma protein-A (PAPP-A), as well as methods for identifying ligands and inhibitors of PAPP-A.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A micro device, such as a brain dust, is arranged for implantation into biological tissue. A power management unit receives a wireless signal, e.g. an ultrasonic signal, from an external source and generates an electric power output accordingly. The micro device has a plurality of electrical power consuming components powered by the electric power output, especially comprising one or more controllable light sources, e.g. micro LEDs which can be controlled to generate light in a time-varying manner, such as for optogenetics or for optical release of a drug. To increase power efficiency, an electric regulator circuit regulates electric current applied to the controllable light source to provide a predetermined total electric load of the power management unit. This provides an optimal efficiency of transferring power to the plurality of electrical power consuming components with a minimal requirement of volume of the circuit which provides impedance matching for optimal efficiency.
The invention regards a system for converting a carbon dioxide source to methane, comprising: a carbon capture reactor comprising a liquid carbon dioxide solvent configured to be biocompatible with methanogens, and a liquid-based biomethanation reactor, wherein the reactors are configured to be in fluid communication such that the liquid carbon dioxide solvent is passed in a forward flow from the carbon capture reactor to the biomethanation reactor.
B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
The present disclosure regards a method for compression of a signal, of length, comprising data, the method comprising the steps of at least for a first level of decomposition, transforming the signal based on a first sparse matrix, of size × formed by an invertible matrix, representing a divisor-based signal decomposition for a first divisor to obtain a first vector of transformation coefficients, wherein =, and wherein the first vector comprises an initial component and detail components,, …,. The method further comprises the step of at least for a second level of decomposition, transforming the initial component based on a second sparse matrix, of size ×, where =, formed by an invertible matrix, representing a divisor-based signal decomposition for a second divisor, to obtain a second vector of transformation coefficients wherein =, and wherein the second vector comprises an initial component and detail components,, …,. After the transformation coefficients of the second vector of transformation coefficients,,, …, and detail components of the first vector,, …,, are quantized to obtain a quantized transformation vector and the signal is compressed based on the quantized transformation vector.
Disclosed are single domain antibody-based constructs, which are useful for treating IgE- related disorders or conditions by facilitating the dissociation of IgE from the high-affinity IgE receptor. Further disclosed are compositions comprising the constructs. Also nucleic acids and vectors are provides, as is methods of treatment of IgE related disorders
The present invention relates to CRISPRa constructs targeting STING for use in cancer treatment. In particular, the present invention relates to CRISPRa constructs targeting STING for use in treatment of cancers having no or low STING expression.
The present invention relates to a method of producing a bulk magnetic material of permanent magnets free of rare-earth metals. Specifically the type of magnets produced by the present invention are rare-earth free magnets based on iron. More specifically, the magnets of the present invention are of the class hexaferrites. The present invention further relates to magnets produced by the method of the invention, which feature misaligned magnetic moments resulting in improved magnetic properties such as higher coercivity.
H01F 1/11 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials non-metallic substances, e.g. ferrites in the form of particles
H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets
47.
DETECTION OF GASTRIC INTRINSIC FACTOR (IF) IN FLUID SAMPLES
The present disclosure relates to compositions and assays for detecting gastric IF in bodily fluids like blood and urine and use of such compositions and assays in detecting IF-related disease conditions.
G01N 33/82 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C07H 23/00 - Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
The present invention relates to a Lactate/Ketone body ester for preservation of vital organ function and combat inflammation and cancer growth. In particular, the present invention relates to a Lactate/Ketone body ester with the beneficial properties of Lactate and beta-hydroxybutyrate (BHB) on vital organ function, inflammation and cancer growth but without the harmful sodium loads following administration of both Lactate and beta-hydroxybutyrate.
C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
49.
TREATMENT PROTOCOL USING INTRALYMPHATIC IMMUNOTHERAPY
Imperial College Innovations Limited (United Kingdom)
Inventor
Hoffmann, Hans Jürgen
Skaarup, Søren Helbo
Schmid, Johannes Martin
Durham, Stephen R.
Abstract
The present invention relates to an improved treatment protocol using Intralymphatic immunotherapy (ILIT). In particular, the present invention relates ILIT in relation to grass allergy.
The present invention relates to a method of producing permanent magnets free of rare-earth metals. Specifically the type of magnets produced by the present invention are rare-earth free magnets based on iron. More specifically, the magnets of the present invention are of the class hexaferrites. The present invention further relates to magnets produced by the method of the invention, which are highly aligned magnets with improved magnetic properties compared to commercially available analogues.
H01F 1/11 - Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials non-metallic substances, e.g. ferrites in the form of particles
H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets
The present disclosure relates to a high-speed laser speckle contrast imaging system for characterizing pressure wave or pulse wave propagation or vascular conducted response in at least one vessel of a biological target, the apparatus comprising: a laser source generating a laser radiation; a high-speed camera configured for capturing at least 1000 frames per second (fps), preferably at least 5000 fps, more preferably 6000 fps of the target; an optical sub-system configured for 1) guiding the laser radiation from the laser source to the target 2) and for collecting and guiding a back-scattered light from the target to the camera; a processing unit configured for receiving and processing raw image data from the camera for calculating at least one feature related to the pressure wave propagation or vascular conducted response.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
A61B 5/021 - Measuring pressure in heart or blood vessels
GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (Germany)
Inventor
Bækkegaard, Thomas
Zinner, Nikolaj Thomas
Kues, Michael
Khodadad Kashi, Anahita
Abstract
The present disclosure relates to generative models, in particular quantum generative models, for example generative adversarial networks (GANs) and in particular quantum adversarial networks, and implementation of generative models in quantum systems. One embodiment relates to a generative model system comprising a generator system comprising a quantum frequency comb system configured for generating sample data, and optionally a discriminator system for distinguishing the sample data from training data.
The present invention relates to a process for processing whole oilseed. In particular, the present invention relates to a process for isolating a protein rich fraction from whole oilseed using acidic pH. The present invention also relates to uses of such protein rich fractions.
A23J 1/14 - Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from press-cake or oil-bearing seeds
C11B 1/04 - Pretreatment of vegetable raw material
C11B 1/10 - Production of fats or fatty oils from raw materials by extracting
A23L 29/238 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
The present invention relates to a process for processing oilseed. In particular, the present invention relates to a process for isolating a protein rich fraction from oilseed using acidic pH. The present invention also relates to uses of such protein rich fractions.
A23J 1/14 - Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from press-cake or oil-bearing seeds
A23K 10/30 - Animal feeding-stuffs from material of fungal origin, e.g. mushrooms
The present disclosure relates to antibodies and antigen-binding fragments thereof binding to SARS-CoV-2 which may neutralize a SARS-CoV-2 infection. Also provided are polynucleotides that encode the antibodies and antigen-binding fragments thereof, vectors, host cells, and related compositions, as well as methods of using the antibodies, nucleic acids, vectors, host cells, and related compositions to prevent or treat a SARS-CoV-2 infection in a subject.
The present invention relates to a Lactate/Ketone body ester for preservation of vital organ function and combat inflammation and cancer growth. In particular, the present invention relates to a Lactate/Ketone body ester with the beneficial properties of Lactate and beta-hydroxybutyrate (BHB) on vital organ function, inflammation and cancer growth but without the harmful sodium loads following administration of both Lactate and beta-hydroxybutyrate.
C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
The invention provides a dry electrode integrated with a garment to be worn by a subject, e.g. a compression stocking. The dry electrode is formed by a layered structure with at least three layers. A first layer of a polyurethane material with a lower side serving to adhere to the garment. A second layer of an electrically conductive material is arranged on, e.g. printed on, an upper side of the first layer. A third layer is in contact with the skin of the subject when wearing the garment. The third layer provides a higher electrical impedance than the second layer, is in contact with the second layer and covers an area large enough to cover both of the first and second layers, so that an edge portion of the third layer adheres directly to the garment. The dry electrode is suitable for neuromuscular electrical stimulation.
A process for synthesizing phosphoramidites by immobilizing a phosphitylating agent on an activated resin to create a loaded resin and then bringing the loaded resin into contact with a suitable substrate. The phosphoramidites are synthesized within minutes from applying the starting materials. Thus, the process makes it possible to create specific phosphoramidites on-demand as they are needed in further applications. The substrates to be applied are mostly nucleosides, thus to create nucleoside phosphoramidites for subsequent oligonucleotide synthesis.
An implantable micro device, or dust, has a piezoelectric transducer connected to a power management circuit, which provides electric power output for powering components of the device based on an ultrasonic power signal from an external ultrasonic signal source. A sensor measures a physical parameter, e.g. a neural activity signal, and generates an electric signal, digitized by a time-encoding analog-to-digital converter, e.g. a delta-sigma modulator, to generate a one-bit data stream representing the sensed parameter. A load modulation circuit with one or more electric switches connected to the transducer modulates transducer electric load according to the one-bit data stream, thus causing a backscattered signal from the piezoelectric transducer to be modulated by the sensed physical parameter. Preferably, the piezoelectric transducer's electric load is harshly modulated by connecting it to either an optimum load for minimum reflection, or short-circuiting for maximum reflection according to each bit of the digitized data stream.
A a front-end device is arranged to amplify an electric signal from an associated sensor, e.g. for amplifying an electric signal from a neural activity sensor. The front-end device has an amplifier circuit connected between its input and output terminals (Vin, Vout), wherein the amplifier circuit comprises a capacitive-coupled chopper circuit comprising a first gain element and first, second and third chopper switches arranged for operating at a chopper frequency. Further, the amplifier circuit has A) an impedance boosting auxiliary path connected to the input terminal in parallel with a first chopper switch of the CCC, wherein the impedance boosting auxiliary path comprises a pre-charging buffer, and B) a second gain element connected in a feedback path of the CCC. Such front-end device has high input impedance, and the input impedance is uncorrelated with the gain. It is highly suited for implantable micro devices, e.g. brain dusts.
H03F 3/387 - Dc amplifiers with modulator at input and demodulator at output; Modulators or demodulators specially adapted for use in such amplifiers with semiconductor devices only
H03F 1/56 - Modifications of input or output impedances, not otherwise provided for
The present invention concerns novel cyclic peptides, and medical uses thereof, such as treatment and/or prevention of diseases of the nervous system, neuropathic pain, and/or mental and behavioural disorders, and related aspects.
C07K 7/64 - Cyclic peptides containing only normal peptide links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
63.
A PROCESS UTILIZING A THERMOMORPHIC DEEP EUTECTIC SOLVENT SYSTEM WITHIN BIOCATALYTIC APPLICATIONS TO RECOVER THE BIOCATALYST AND THE PRODUCTS
The present invention relates to a process utilizing a thermomorphic deep eutectic solvent system within biocatalytic applications to recover the biocatalyst and the products. Another aspect of the present invention relates to a thermomorphic deep eutectic solvent system for performing a biocatalytic reaction comprising a deep eutectic solvent and a polar solvent.
C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
C12P 7/22 - Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
C07C 237/00 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
B01D 11/04 - Solvent extraction of solutions which are liquid
System and a method for detecting corrosion or cracks in a metal structure embedded in concrete. Piezoelectric transducers are arranged for contact with the metal structure embedded in the concrete; an electronic circuit generate an electric test signal for the piezoelectric transducers and receives an electric return signal from the piezoelectric transducers. The electronic circuit comprises an analysis circuit for analysing the electric return signal and for storing the result of the analysis until the results can be communicated to an external device.
Compounds and methods for treating infertility or reduced fertility in a female individual are provided, wherein a method includes taking primordial follicles from said individual, treating said follicles in vitro with an NRF2 modulator and re-inserting the treated follicles into said individual. An in vitro method of regulating primordial follicle maturation is provided, wherein the method includes contacting primordial follicles and an NRF2 modulator.
A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
A61K 9/00 - Medicinal preparations characterised by special physical form
C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues
A61P 15/08 - Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The present invention relates to single domain antibodies and multispecific antibodies that a) bind to the allergen from honeybee venom Api m 1 or Api m 2, b) exhibit non-overlapping epitopes with other antibodies, c) exhibit favourable kinetic properties; and/or d) have the ability to block the binding of IgE to the allergen. The present invention also relates to uses of these single domain antibodies and multispecific antibodies, in particular in the treatment or prevention of bee allergy. Figure 1B to be published with the abstract.
The present disclosure relates to a radiotherapy system comprising at least one radiation source comprising a particle accelerator and a control unit for configuring the at least one radiation source. The system is configured in a first configuration to irradiate one or more sub-volumes and/or adjacent volumes of a target using at least one monoenergetic proton ultra-high dose rate beam and a second configuration to irradiate a remaining volume of the target using a non-ultra-high dose rate beam, wherein the radiation is delivered using a range of energies. The present disclosure further relates to computer-implemented method of operating a radiotherapy system.
The present invention relates to a method for disassembly of epoxy-based polymers or composites of fibres reinforced with such polymers, the method comprising chemical manipulations of the polymer involving an organometallic catalyst in an organic solvent mixture allowing for recycling of the constituents comprised in the epoxy-basedpolymer or composites thereof.
C08J 11/18 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material
C08J 11/28 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic compounds containing nitrogen, sulfur or phosphorus
B29B 17/02 - Separating plastics from other materials
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
e.g.,e.g., proteinaceous fusion constructs that comprise a complement 3- and pregnancy zone protein–like, alpha-2-macroglobulin domain–containing (CPAMD) protein (e.g., A2M) and one or more drugs and function as protease-activatable prodrugs.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61M 21/02 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
H04R 3/12 - Circuits for transducers for distributing signals to two or more loudspeakers
The present disclosure regards a qubit circuit comprising at least first and second data qubits and a mediator qubit coupling the first and second data qubits in a circuit plane, wherein the first data qubit and the second data qubit are coupled to the mediator qubit by means of respective twist couplers, each twist coupler comprising superconducting regions connected by superconducting transmission lines, wherein at least two of the connecting transmission lines cross each other at a line crossing point where the crossing transmission lines are separated by an insulator layer.
The present disclosure regards a qubit circuit comprising at least first and second data qubits and a mediator qubit coupling the first and second data qubits in a circuit plane, wherein the first data qubit and the second data qubit are coupled to the mediator qubit by means of respective twist couplers, each twist coupler comprising superconducting regions connected by superconducting transmission lines, wherein at least two of the connecting transmission lines cross each other at a line crossing point where the crossing transmission lines are separated by an insulator layer.
The present invention relates to a proteinaceous compound comprising a first binding moiety, such as an antibody or fragment thereof, having affinity for a target of interest, and a pMHC comprising an MHC molecule, such as an HLA molecule, presenting an antigenic peptide, wherein the presented antigenic peptide has affinity for CD8+ T-cells induced by the antigenic peptide, such as induced by vaccination. The present invention further relates to the proteinaceous compound for use as a medicament. Also, the present invention relates to the proteinaceous compound for treatment of cancer and for treating of a subject infected with a pathogen.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/74 - Major histocompatibility complex (MHC)
75.
DEVICE AND METHOD FOR PET IMAGE ANALYSIS AND RECONSTRUCTION
A device and a method for image reconstruction for medical imaging is provided. The method comprises obtaining a lookup table of pre-computed sets of data, obtaining a PET image, dividing the PET image into subset-images of one, or more, pixels. For each subset-image of pixels in the PET image, an extended rejection sampler is used to select model-images from the lookup table, determining and outputting a representation image based on the posterior distribution.
The present invention relates to methods for treating or preventing viral infection, or disease or complications associated with viral infection, in particular infection by a coronavirus or influenza virus, optionally SARS-CoV-2, SARS-CoV or MERS-CoV. The invention relates particularly to methods for treating or preventing COVID- 19.
The present disclosure relates to the field of radiotherapy, in particular, methods of and apparatus for treating cancer using ultra-high dose rate radiotherapy (FLASH). The apparatus may comprise a device configured to administer to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively. The device may be configured such that the treatment is sufficient to prevent further growth of the tumor for at least 10% longer than standard of care radiotherapy, induce at least 10% more tumor regression than standard of care radiotherapy and/or delay tumor regrowth by at least about 2 months longer than standard of care radiotherapy.
The present invention relates to methods for treating or preventing viral infection, or disease or complications associated with viral infection, in particular infection by a coronavirus or influenza virus, optionally SARS-CoV-2, SARS-CoV or MERS-CoV. The invention relates particularly to methods for treating or preventing COVID- 19.
The present disclosure relates to the field of radiotherapy, in particular, methods of and apparatus for treating cancer using ultra-high dose rate radiotherapy (FLASH). The apparatus may comprise a device configured to administer to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively. The device may be configured such that the treatment is sufficient to prevent further growth of the tumor for at least 10% longer than standard of care radiotherapy, induce at least 10% more tumor regression than standard of care radiotherapy and/or delay tumor recurrence by at least about 2 months longer than standard of care radiotherapy.
The present invention relates to inactivated stem cells, which can be stored for several days in a refrigerator (above 0°C, preferably in the range 0.1-10°C) and still maintain their cellular and phenotypic integrity as well as therapeutic potential. In particular, the present invention relates to medical uses of such refrigerator-stored inactivated stem cell solution.
Some analogues (eg. 3-carbamoyl-1-(tetrahydro-2H-pyran-4-yl)pyridin-1-ium, 3-carboxy-1-isopropylpyridin-1-ium, 1-benzyl-3-carbamoylpyridin-1-ium, 3-carbamoyl-1-methylpyridin-1-ium and cyclopamine) are disclosed to treat female infertility as the compounds increase the percentage of primary follicles relative to primordial follicles compared to control samples.
A61P 15/08 - Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
82.
FUSION PROTEINS COMPRISING ANTI C3B ANTIBODIES FOR COMPLEMENT REGULATION
The present application relates to a fusion protein comprising: an antibody or antigen- binding fragment thereof that binds to C3b; and a polypeptide that binds to C3b, wherein the polypeptide comprises: (i) the amino acid sequences according to SEQ ID NO: 11 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 11; and (ii) the amino acid sequences according to SEQ ID NO: 12 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12, wherein the antibody or antigen-binding fragment thereof of the fusion protein does not compete for binding to C3b with the polypeptide of the fusion protein. The application also provides polypeptides, nucleic acids, vectors and methods of preparing these as well as methods of treatment and pharmaceutical compositions.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
83.
FUSION PROTEINS COMPRISING ANTI C3B ANTIBODIES FOR COMPLEMENT REGULATION
The present application relates to a fusion protein comprising: an antibody or antigen- binding fragment thereof that binds to C3b; and a polypeptide that binds to C3b, wherein the polypeptide comprises: (i) the amino acid sequences according to SEQ ID NO: 11 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 11; and (ii) the amino acid sequences according to SEQ ID NO: 12 or a variant thereof having at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12, wherein the antibody or antigen-binding fragment thereof of the fusion protein does not compete for binding to C3b with the polypeptide of the fusion protein. The application also provides polypeptides, nucleic acids, vectors and methods of preparing these as well as methods of treatment and pharmaceutical compositions.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A61P 37/00 - Drugs for immunological or allergic disorders
84.
AN OPTICAL SYSTEM FOR FREQUENCY CONVERSION OF A SINGLE PHOTON
The invention relates to an optical system for converting the frequency, and thereby the wavelength, of a single photon and a method for converting the frequency of a single photon by difference-frequency generation (DFG). Further, the invention relates to a frequency converter. A single photon with a first wavelength (λp) and a laser irradiation with a second wavelength (λi) are arranged for combining in a multiplexer and transmitted to a nonlinear waveguide. The multiplexer comprises two input waveguides for receiving the single photon and the laser irradiation and is combining them in one of the waveguides from where it is transmitted to the nonlinear waveguide. In the nonlinear waveguide, the single photon interacts with the laser irradiation and the material of the nonlinear waveguide, so as to frequency convert the single photon from the first wavelength (λp) to a third wavelength (λs). The multiplexer and the nonlinear waveguide are structurally integrated on a compact platform, preferable a photonic integrated circuit (PIC), by being grown on the platform or bonded to the platform.
The present invention concerns an anti-sortilin antibody or an antigen binding fragment thereof, for use in the treatment or prevention of a disease of the eye, in particular diseases or disorders of the retina, the choroid and/or the optic nerve.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
The present invention concerns an external aortic annuloplasty ring for positioning around the circumference of an aortic valve for external aortic root repair or stabilization of the annulus to support the aortic valve, wherein the ring is open- ended and thereby having two opposite open ends, wherein the ring comprises at least two sections with different elastic properties along the perimeter of the ring, and wherein said opposite open ends are suitable for being joined together, such as by suturing, so as to form a closed ring around the aortic root. The invention further concerns a method for manufacturing such a ring.
The present disclosure provides macrocyclic compounds comprising a 4-amido-2,4-pentadienoate (APD) moiety. The compounds exhibit toxicity that is selective to the hypoxic micro-environments often found in cancerous tissues. The disclosed compounds are therefore suitable for treatment of hypoxic cancer cells.
C07D 273/00 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to an RNA aptamer comprising a sequence having at least 80% sequence identity to SEQ ID NO: 1 for targeting RBD of the spike protein of SARS-CoV-2 virus as well as multimeric RNA aptamers. The invention furthermore relates to the RNA aptamer and/or multimeric RNA aptamers for use in preventing, alleviating and/or treating infection with SARS-CoV-2 or variants thereof. In addition, an in vitro use of the RNA aptamer and/or multimeric RNA aptamer in a detection assay is described along with a detection device and a kit of parts for detecting or quantifying SARS-CoV-2 or variants thereof comprising at least one RNA aptamer and/or at least one multimeric RNA aptamer; and a detection device arranged for capturing said RNA aptamer and/or said multimeric RNA aptamer.
The present invention concerns a polynucleotide construct encoding a mini-receptor of SORLA. The present invention further concerns a vector, a cell and/or a composition comprising said polynucleotide construct. The present invention further concerns a polypeptide representing a mini-receptor of SORLA. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in medicine. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in treatment, prevention and/or alleviation of Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of treating Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of increasing sAPP? in a cell. The present invention further concerns a method of decreasing A?38, A?40, and/or A?42 in a cell.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
90.
CGMP COMPLIANT PRODUCTION AND EXPANSION OF PLASMACYTOID DENDRITIC CELLS FROM HEMATOPOIETIC STEM AND PROGENITOR CELLS
HSPC-derived Plasmacytoid dendritic cells (HSPC-pDCs) constitute a rare type of immune cell with multifaceted functions that bridge pivotal parts of the immune system. Biological studies of blood-derived HSPC-pDCs and their potential use as a cell-based immunotherapy have long been challenged by the scarce amounts of HSPC-pDCs that can be extracted from blood samples. This invention is related to a process for HSPC-pDC production applicable for clinical use, which involves in vitro differentiation of hematopoietic stem and progenitor cells (HSPCs). With this optimized GMP-compliant protocol, we generated an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord-blood derived HSPCs, and we also show that the protocol enables robust HSPC-pDC generation from HSPCs extracted from whole blood. The produced cells display a pDC phenotype (Lin-/CD11c-/CD123+/CD303+) and the ability to produce high levels of type I interferon upon TLR7 and TLR9 stimulation.
The present disclosure concerns antisense oligonucleotide (ASO) capable of binding to a target site on the pre-mRNA of SORL1. The present disclosure further concerns a composition comprising said ASO. The present disclosure further concerns an ASO for use in medicine. The present disclosure further concerns an ASO for use in the prevention, treatment and/or alleviation of Alzheimer's Disease (AD), or a disease or disorder associated with Alzheimer's Disease. The present disclosure further concerns a method for mediating exon skipping in SORL1 transcripts, a method of determining the efficiency of ASO mediated SORL1 exon skipping, a method for testing if a patient identified with a SORL1 mutation will benefit from treatment with an ASO mediating exon skipping, and a method of producing an ASO.
HSPC-derived Plasmacytoid dendritic cells (HSPC-pDCs) constitute a rare type of immune cell with multifaceted functions that bridge pivotal parts of the immune system. Biological studies of blood-derived HSPC-pDCs and their potential use as a cell-based immunotherapy have long been challenged by the scarce amounts of HSPC-pDCs that can be extracted from blood samples. This invention is related to a process for HSPC-pDC production applicable for clinical use, which involves in vitro differentiation of hematopoietic stem and progenitor cells (HSPCs). With this optimized GMP-compliant protocol, we generated an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord-blood derived HSPCs, and we also show that the protocol enables robust HSPC-pDC generation from HSPCs extracted from whole blood. The produced cells display a pDC phenotype (Lin-/CD11c-/CD123+/CD303+) and the ability to produce high levels of type I interferon upon TLR7 and TLR9 stimulation.
The present invention concerns a polynucleotide construct encoding a mini-receptor of SORLA. The present invention further concerns a vector, a cell and/or a composition comprising said polynucleotide construct. The present invention further concerns a polypeptide representing a mini-receptor of SORLA. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in medicine. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in treatment, prevention and/or alleviation of Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of treating Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of increasing sAPPα in a cell. The present invention further concerns a method of decreasing Aβ38, Aβ40, and/or Aβ42 in a cell.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
94.
WIND TURBINE WITH COMBINED PITCH AND RADIAL DISPLACEMENT COUPLING AND CONTROL METHOD
The invention relates to a wind turbine rotor comprising a rotor hub, aerodynamic blades radially extending away from the rotor hub and may be configured to generate lift, torque or lift that imposes a torque, to rotate the rotor upon being exposed to wind, said aerodynamic blades may each have a root and a tip, a connecting element connecting each aerodynamic blade with the rotor hub, said connecting element may be configured to enable a radial displacement of the whole of each aerodynamic blade between an innermost position and an outermost position of the whole of each aerodynamic blade, said connecting element may comprise a mechanical coupling between the radial displacement of the aerodynamic blade and the pitch of the aerodynamic blade so that a radial displacement of the aerodynamic blades may provide a change in pitch of the aerodynamic blade and/or so that a change in pitch of the aerodynamic blade provides a radial displacement of the aerodynamic blade.
The present invention relates to a lentivirus-derived particle comprising one or more Cas9-like proteins and at least one optimized sgRNA, wherein the optimized sgRNA comprises a targeting region and a non-targeting region, wherein said non-targeting region comprises a nucleotide sequence corresponding to SEQ ID NO: 1 or sequences having at least 90% sequence identity to SEQ ID NO: 1, said nucleotide sequence further comprising at least the following modifications: an extended repeat-anti-repeat region comprising a first extension of 2-8 base pairs in the repeat-anti-repeat region corresponding to nucleotides 1-12 and 17-30 of SEQ ID NO: 1; and optionally, an extended stem-loop 2 region comprising a second extension of 2-8 base pairs in the stem-loop 2 corresponding to the nucleotides 48-61 of SEQ ID NO: 1; and/or optionally, an A-U flip of the nucleotides corresponding to nucleotides 5 and 36 of SEQ ID NO: 1.
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (France)
UNIVERSITÉ D'AIX MARSEILLE (France)
AARHUS UNIVERSITET (Denmark)
Inventor
Etzerodt, Anders
Lawrence, Toby
Abstract
Experimental and clinical evidence suggests tumor-associated macrophages (TAM) play important roles in cancer progression. Here, the inventors show that the omentum is a critical pre-metastatic niche for development of invasive disease in this model and defined a unique subset of CD163+ Tim4+ tissue-resident macrophages in omentum of embryonic origin and maintained independently of bone marrow-derived monocytes. Transcriptomic analysis showed that resident CD163+ Tim4+ omental macrophages were phenotypically distinct and maintained their resident identity during tumor growth. Selective depletion of CD163+ Tim4+ macrophages in omentum using genetic and therapeutic tools prevented tumor progression and metastatic spread of disease. The molecular pathways of cross-talk between tissue-resident macrophages and disseminated cancer cells may represent new targets to prevent metastasis and disease recurrence. Thus the present invention relates to a method of treating ovarian cancer, breast cancer and pancreatic cancer in a subject in need thereof comprising administering to the subject a therapeutically effective of an agent capable of depleting the population of CD163+ Tim4+ tumor associated macrophages.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to thin filters comprising melt electro spinning writing (MEW) fibers for capturing and culturing circulating tumor cells (CTCs). The invention further relates to processes for producing the filters, methods for capturing and culturing CTCs using the filters, kits and devices comprising the filters and uses of the filters.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Software; Computer programmes for data processing; Electronic entry systems. Development and testing of computing methods, algorithms and software; Software development; Project studies relating to software; Computer software research; Computer programming and software design; Software as a service [SaaS]; Software development, programming and implementation.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Software; Computer programmes for data processing; Electronic entry systems. Development and testing of computing methods, algorithms and software; Software development; Project studies relating to software; Computer software research; Computer programming and software design; Software as a service [SaaS]; Software development, programming and implementation.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Software; Computer programmes for data processing; Electronic entry systems. Development and testing of computing methods, algorithms and software; Software development; Project studies relating to software; Computer software research; Computer programming and software design; Software as a service [SaaS]; Software development, programming and implementation.
